(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
First foreign troop in new gang suppression force lands in Haiti to replace previous mission- Artemis 2 astronauts — now halfway to the moon — report 'burning smell' from toilet, but everything's fine
- Parents search for children missing since a volcanic eruption in Colombia 40 years ago
- Miss 'Stranger Things' already? Here's how you can get your Upside Down fix in 2026 with spinoffs, games and more
- Check out the exclusive pitch deck Valerie Health used to raise $30 million from Redpoint Ventures to automate healthcare faxes
- Dark matter obeys gravity after all — could that rule out a 5th fundamental force in the universe?
- Where America’s CO2 emissions come from – what you need to know, in charts
- BravoCon 2025: How to watch, full schedule and lineup, where to stream free and more
- Eight arrested in joint Scotland and Spain gang raids
